Global Immuno-Oncology Market Going to Expand at 16.5% CAGR by 2025

Browse Complete Report @ http://www.persistencemarketresearch.com/market-research/immunooncology-market.asp

Collaborative efforts and initiatives to identify therapies for difficult-to-treat illnesses is a key factor driving the overall immune-oncology market. However, high drug pricing, development costs and limited technical expertise are some of the challenges likely to dampen the surging spirit of the market over 2025.

Currently, immune checkpoint inhibitor therapy is widely used for treating several carcinogenic disorders. Immune checkpoint inhibitor drugs help the body fight against certain proteins that are normally used by various tumors to suppress immune responses. Sales revenue from immune checkpoint inhibitors drugs is anticipated to reach US$ 7,321.7 Mn by 2017-end. Of late, a number immune checkpoint inhibitor drugs have been approved by the US FDA including Yervoy (anti-CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1). Demand for these drugs is expected to further gain traction, owing to a significant investment by biopharmaceutical companies in developing a robust pipeline. Meanwhile, immune system modulator is the second most preferred immune-oncology therapy and is expected to create an incremental opportunity of US$ 659.9 Mn between 2017 and 2025. Two major approved drugs that fall in this category include interferons and interleukins.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/11329

Based on therapeutic area, demand for immune-oncology therapeutics for melanoma will remain high throughout the forecast period. By end user, hospitals account for the largest revenue share of the market and are expected to represent around US$ 5,557.1 Mn by 2017-end.

Amongst regions, the immuno-oncology market in North America accounted for a revenue share of around 67.1% in 2016. The region’s market is expected to witness a strong CAGR of 17.1% during the assessment period and retain its top position. In terms of revenue, the US dominates the North America immuno-oncology market and is projected to continue to do so in 2017 and beyond owing to the presence of prominent drug manufacturing companies in the country.

Request to view table of content @ http://www.persistencemarketresearch.com/market-research/immunooncology-market/toc

PMR is its report has profiled some of the leading companies operating in the global immuno-oncology market, which includes Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb, Dendreon Corporation, F.Hoffmann-La Roche, Merck & Co., Inc. Novartis AG, Pfizer, Inc., Sanofi. In terms of revenue share, Bristol-Myers Squibb (BMS) was ranked at the top in 2016, thanks to the success of its blockbuster products Opdivo and Yervoy.